• A novel biallelic splice-site variant in the LRP4 gene causes sclerosteosis 2
• A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone
• A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis
• A Novel Mutation in a Gene Causes Sclerosteosis in a Family of Mediterranean Origin
• A Review of the Clinical, Radiological and Biochemical Characteristics and Genetic Causes of High Bone Mass Disorders
• Absence of sclerostin adversely affects B-cell survival
• An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling
• An auditory profile of sclerosteosis
• Anatomical similarity between the Sost-knockout mouse and sclerosteosis in humans
• Antagonists of Wnt pathway
• Anti-sclerostin - is there an indication?
• Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling
• BMP signaling in development and diseases: a pharmacological perspective
• Clinical utility of serum sclerostin measurements
• Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development
• Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice
• Cranial reconstruction for treatment of intracranial hypertension from sclerosteosis: case-based update
• Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097
• Deficiency of lrp4 in zebrafish and human LRP4 mutation induce aberrant activation of Jagged-Notch signaling in fin and limb development
• Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions
• Differential diagnosis of a diffuse sclerosis in an identified male skull (early 20th century Coimbra, Portugal): A multimethodological approach for the identification of osteosclerotic dysplasias in skeletonized individuals
• Disease co-morbidity and the human Wnt signaling pathway: a network-wise study
• Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations
• Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice
• Examining craniofacial variation among crispant and mutant zebrafish models of human skeletal diseases
• Expression and regulation of the SOST gene
• From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
• Genetic control of bone mass
• Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models
• Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
• Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third beta-Propeller Domain Can Cause Sclerosteosis
• Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third β-Propeller Domain Can Cause Sclerosteosis
• Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5
• Investigation of the Underlying Mechanism of Sclerosteosis Expression in Muscle Tissue in Multiple Myeloma with Sarcopenia
• Localization of the gene for hyperostosis cranialis interna to chromosome 8p21 with analysis of three candidate genes
• Looking for new anabolic treatment from rare diseases of bone formation
• Low magnitude vibration alleviates age-related bone loss by inhibiting cell senescence of osteogenic cells in naturally senescent rats
• LRP receptor family member associated bone disease
• Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption
• LRP4 site-specific variants in the third β-propeller domain causes congenital myasthenic syndrome type 17
• LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner
• Management of trigeminal neuralgia in sclerosteosis
• Maxillo-facial radiology case 124
• Mef2c regulates bone mass through Sost-dependent and -independent mechanisms
• Miscellaneous Bone Disorders
• Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion
• Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition
• Mutations in the fourth β-propeller domain of LRP4 are associated with isolated syndactyly with fusion of the third and fourth fingers
• N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction
• Neurological manifestations in patients and disease carriers in an Italian family with osteosclerosis
• New mutation in the β1 propeller domain of LRP4 responsible for congenital myasthenic syndrome associated with Cenani-Lenz syndrome
• Novel insights on the effect of sclerostin on bone and other organs
• Novel SOST gene mutation in a sclerosteosis patient and her parents
• Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report
• Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders
• Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020
• Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover
• Positive and Negative Regulators of Sclerostin Expression
• Recombinant sclerostin inhibits bone formation <em>in vitro</em> and in a mouse model of sclerosteosis
• Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis
• Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity
• Role and mechanism of action of sclerostin in bone
• Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
• Role of Sost in Wnt signal pathway in osteoporosis rats and regulating effect of soybean isoflavones on Wnt signal pathway
• Sclerosteosis (craniotubular hyperostosis-syndactyly) with complex hyperphalangy of the index finger
• Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family
• Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review
• Sclerosterosis (Truswell-Hansen disease)
• Sclerostin ablation prevents aortic valve stenosis in mice
• Sclerostin and skeletal health
• Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania
• Sclerostin deficiency in humans
• Sclerostin deficiency is linked to altered bone composition
• Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction
• Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome
• Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition
• Sclerostin: a novel target for intervention in the treatment of osteoporosis
• Sclerostin: clinical insights in muscle-bone crosstalk
• Sclerostin: From bedside to bench, and back to bedside
• Sclerostin: from bench to bedside
• Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
• Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders
• Sclerostin: recent advances and clinical implications
• Sclerostin: therapeutic horizons based upon its actions
• Serum Dickkopf 1 levels in sclerostin deficiency
• Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner
• SOST Deficiency Aggravates Osteoarthritis in Mice by Promoting Sclerosis of Subchondral Bone
• Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice
• Targeted deletion of Sost distal enhancer increases bone formation and bone mass
• The genetics of bone mass and susceptibility to bone diseases
• The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans
• The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases
• The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis
• Titanium particles damage osteocytes and inhibit osteoblast differentiation
• Toll-like receptor-2 induced inflammation causes local bone formation and activates canonical Wnt signaling
• Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers
• Wnt and the Wnt signaling pathway in bone development and disease
• Wnt signaling in bone formation and its therapeutic potential for bone diseases
• WNT signaling in bone homeostasis and disease: from human mutations to treatments
• Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches